(Q38083754)

28 August 2017

title

Review article: the treatment of genotype 1 chronic hepatitis C virus infection in liver transplant candidates and recipients (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

1 reference

D Joshi

1

1 reference

28 August 2017

I Carey

series ordinal

2

1 reference

28 August 2017

K Agarwal

series ordinal

3

1 reference

28 August 2017

language of work or name

English

0 references

publication date

21 February 2013

1 reference

Alimentary Pharmacology & Therapeutics

28 August 2017

published in

1 reference

28 August 2017

volume

37

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

659-671

1 reference

Global challenges in liver disease

28 August 2017

cites work

1 reference

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

21 January 2018

1 reference

Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry

21 January 2018

1 reference

Long-term outcome of hepatitis C infection after liver transplantation

21 January 2018

1 reference

The association between hepatitis C infection and survival after orthotopic liver transplantation

21 January 2018

1 reference

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Hyporesponsiveness to PegIFNα2B plus ribavirin in patients with hepatitis C-related advanced fibrosis

21 January 2018

1 reference

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.

21 January 2018

1 reference

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension

21 January 2018

1 reference

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus

21 January 2018

1 reference

High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.

21 January 2018

1 reference

The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C.

21 January 2018

1 reference

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

21 January 2018

1 reference

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients.

21 January 2018

1 reference

Reinfection of liver graft by hepatitis C virus after liver transplantation

21 January 2018

1 reference

Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.

21 January 2018

1 reference

Fibrosis progression in hepatitis C positive liver recipients after sustained virologic response to antiviral combination therapy (interferon-ribavirin therapy).

21 January 2018

1 reference

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation

21 January 2018

1 reference

Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation.

21 January 2018

1 reference

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

21 January 2018

1 reference

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

21 January 2018

1 reference

Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation.

21 January 2018

1 reference

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination

21 January 2018

1 reference

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

21 January 2018

1 reference

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

21 January 2018

1 reference

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin

21 January 2018

1 reference

Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies.

21 January 2018

1 reference

Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis

21 January 2018

1 reference

Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy

21 January 2018

1 reference

Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study

21 January 2018

1 reference

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus

21 January 2018

1 reference

Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis.

21 January 2018

1 reference

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

21 January 2018

1 reference

The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study

21 January 2018

1 reference

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

21 January 2018

1 reference

Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin a, on interferon-induced antiviral protein in human hepatocyte cells

21 January 2018

1 reference

Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence

21 January 2018

1 reference

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation

21 January 2018

1 reference

Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.

21 January 2018

1 reference

Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant

21 January 2018

1 reference

Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin

21 January 2018

1 reference

Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients

21 January 2018

1 reference

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus.

21 January 2018

1 reference

Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12260

1 reference

28 August 2017

1 reference